{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"Number of patients who have an additional significant toxicity coded using Common Terminology Criteria for Adverse Events Version 5.0 after experiencing two dose reductions from their assigned treatment dose.","groups":[{"description":"Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.\n\nLenalidomide: Given PO\n\nPharmacological Study: Correlative studies","id":"OG000","title":"Arm I (Low-dose Lenalidomide)"},{"description":"Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.\n\nLenalidomide: Given PO\n\nPharmacological Study: Correlative studies","id":"OG001","title":"Arm II (High-dose Lenalidomide)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only eligible patients are considered in the analysis of this outcome measure","reportingStatus":"POSTED","timeFrame":"While receiving protocol therapy up to 3 years after study enrollment","title":"Number of Patients With Toxic Events After 2 Dose Reductions","type":"SECONDARY","unitOfMeasure":"Participants"}